What we do
ExQor is developing a range of non-invasive, CNS healthcare solutions.
ExQor is using its multi-patented bio-nanoparticle to develop a new drug to prevent neurodegeneration and to spur both disease resistance and cell growth. The development is NIH funded.
ExQor is also using its multi-patented bio-nanoparticle to develop a new drug to treat CNS metastases.
Why we are unique
In vivo results show that ExQor’s bio-nanoparticle is up to 300 times more effective in delivering large molecule drugs to the CNS than any other drug delivery method. ExQor's platform has a robust functionalization capability, and can simultaneously carry multiple types of drug cargo.
ExQor’s multi-patented bio-nanoparticle is natively capable of non-invasively transporting different types of large or small molecule drugs across an intact blood brain barrier and also across cell membranes, and delivering the drugs in efficacious concentration.